All data are based on the daily closing price as of October 9, 2024

OBI Pharma’s OBI-992 Shortlisted for “Most Promising Clinical Candidate” at 2024 World ADC Awards

The TROP2-targeting ADC is currently in phase I/II trials for advanced solid tumors, including gastric cancer
Taiwan
o 4174.TWO Mid and Small Cap 2000
Share this on

OBI Pharma, Inc. announced that its antibody-drug conjugate (ADC), OBI-992, has been shortlisted as one of eight finalists for the “2024 Most Promising Clinical Candidate” at the 11th Annual World ADC Awards. This recognition highlights the potential of OBI-992, which targets the TROP2 protein, commonly overexpressed in several cancers. Winners will be announced on November 6, 2024, at the World ADC Conference in San Diego, California.

OBI-992 is currently in phase I/II clinical trials in the U.S. for patients with advanced solid tumors, including gastric and lung cancers. The drug received Orphan Drug Designation from the FDA in August 2024 for treating gastric cancer. Preclinical data suggests that OBI-992 offers enhanced serum stability, a bystander effect capable of killing neighboring cancer cells, and potential resistance to drug tolerance, setting it apart from other TROP2 ADCs.

OBI Pharma sees this recognition as a validation of its innovative approach in the ADC field. The company is committed to advancing OBI-992’s development, aiming to offer more effective treatment options for cancer patients globally.

Share this on
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top